Plant growth promotion in cereal and leguminous agricultural important plants: from microorganism capacities to crop production.

Plant growth-promoting rhizobacteria (PGPR) are free-living bacteria which actively colonize plant roots, exerting beneficial effects on plant development. The PGPR may (i) promote the plant growth either by using their own metabolism (solubilizing phosphates, producing hormones or fixing nitrogen) or directly affecting the plant metabolism (increasing the uptake of water and minerals), enhancing root development, increasing the enzymatic activity of the plant or "helping" other beneficial microorganisms to enhance their action on the plants; (ii) or may promote the plant growth by suppressing plant pathogens. These abilities are of great agriculture importance in terms of improving soil fertility and crop yield, thus reducing the negative impact of chemical fertilizers on the environment. The progress in the last decade in using PGPR in a variety of plants (maize, rice, wheat, soybean and bean) along with their mechanism of action are summarized and discussed here.

Biological behavior due to cell proliferation markers of gastrointestinal stromal tumors.

BACKGROUND/AIMS: The mitotic index and tumor size are currently the main prognostic indicators of gastrointestinal stromal tumors (GIST). The purpose of this study is to investigate the expression of different immunohistochemical markers and their relation to mortality and relapse, and especially concerning high-risk tumors. METHODOLOGY: We did a retrospective study of 68 patients who underwent surgery from 1997 to 2007 with a diagnostic of gastrointestinal stromal tumor. RESULTS: The median follow-up period was 29 months. Relapse and mortality rates were 35.3% (24 cases) and 41.2% (28 cases), respectively. The mitotic index was related to p53 and the cellular proliferation index -Ki67- (p = 0.006 and p = 0.003, respectively). Considering both high and intermediate-risk neoplasms, a significant relation to Ki67 was obtained (p = 0.008). Relapse was related to the mitotic index (p = 0.032) and Ki67 (p = 0.024). Concerning mortality, statistically significant results were obtained with necrosis variables (p = 0.02), mitotic index (p = 0.013), p53 (p = 0.024) and Ki67 (p = 0.033). CONCLUSIONS: Ki67 could be considered a prognostic marker for both relapse and mortality. Concerning high risk GIST, the usefulness the p53 protein and Ki67 nuclear antigen markers was also evident concerning relapse and mortality.

[Quality indicators in bariatric surgery: weight loss valoration]. / Indicadores de calidad en cirugía bariátrica: Valoración de la pérdida de peso.

The medical management of MO may be effective in the short and intermediate terms, although it usually fails then leading to surgical management. Our goal is to assess Capella's surgical technique by means of quality indicators including weight loss. The present work has been performed with surgical MO patients at the 12 de Octubre University Hospital during 2000-2001, and registering the follow-up checkups for the period 2000-2001/2003-2004. We reviewed the clinical charts of 23 patients. The average Body Mass Index (BMI) was 52.24 +/- 10.07 kg/m(2), (range, 41-74.41). When compiling the statistical results, we observed statistically significant post-surgical decreases with no differences whether the PEIMCP outcome was excellent (>or= 65%), fair (= 50-65%) or failure (or= 60 kg/m(2).

Indicadores de calidad en cirugía bariátrica. Valoración de la pérdida de peso / Quality indicators in bariatric surgery. Weight loss valoration

El tratamiento médico de la OM puede resultar efectivo a corto y medio plazo, pero generalmente termina por fracasar, recurriéndose entonces al tratamiento quirúrgico. Nuestro objetivo es evaluar la técnica quirúrgica de Capella mediante unos indicadores de calidad entre los que se encuentra la valoración de la pérdida de peso. El presente estudio se ha llevado a cabo en los pacientes intervenidos quirúrgicamente de OM en el Hospital Universitario 12 de Octubre durante el bienio 2000-2001, recogiéndose los controles evolutivos del trienio 2000-2001/2003-2004. Se analizaron las historias de 23 pacientes. El Índice de Masa Corporal (IMC) medio fue de 52,24 ± 10,07 kg/m2, (rango, 41-74,41). Compendiando los resultados estadísticos se constataron descensos postoperatorios estadísticamente significativos, no percibiéndose diferencias para estas variables en función de si el resultado del PEIMCP fue excelente (≥ 65%), bueno (= 50-65%) o fracaso (≤ 50%), en los siguientes parámetros: IMC (p ≤ 0,001). Comorbilidades (p ≤ 0,001). Hemoglobinemia (p ≤ 0,005). Glucemia (p ≤ 0,001). Triglicéridemia (p ≤ 0,001). Colesterolemia Total (p ≤ 0,001). Sideremia (p ≤ 0,001). Cianocobalamina Sérica (p ≤ 0,001). Sin poder demostrarse alteraciones estadísticamente significativas en los parámetros restantes. Pero con la presunción de que la ausencia de evidencia no significa evidencia de ausencia; es decir, los resultados han sido obtenidos para un tamaño muestral pequeño (N = 23), por lo que no se pueden considerar necesariamente concluyentes. Considerando el porcentaje del exceso del índice de masa corporal perdida como uno de los índices de calidad en cirugía bariátrica, podríamos afirmar que el by-pass gástrico de Capella resulta eficiente en los pacientes obesos con un IMC ≤ 50 kg/m2, dudosamente efectivo en pacientes con un IMC comprendido entre los 50-60 kg/m2 e ineficaz en los pacientes superobesos con un IMC ≥ 60 kg/m2 (AU)

The medical management of MO may be effective in the short and intermediate terms, although it usually fails then leading to surgical management. Our goal is to assess Capella's surgical technique by means of quality indicators including weight loss. The present work has been performed with surgical MO patients at the 12 de Octubre University Hospital during 2000-2001, and registering the follow-up checkups for the period 2000-2001/2003-2004. We reviewed the clinical charts of 23 patients. The average Body Mass Index (BMI) was 52.24 ± 10.07 kg/m2, (range, 41-74.41). When compiling the statistical results, we observed statistically significant post-surgical decreases with no differences whether the PEIMCP outcome was excellent (≥ 65%), fair (= 50-65%) or failure (≤ 50%) in the following parameters: BMI (p ≤ 0.001); Comorbidities (p ≤ 0.001); Hemoglobinemia (p ≤ 0.005); Glycemia (p ≤ 0.001); Triglyceridemia (p ≤ 0.001); Total cholesterolemia (p ≤ 0.001); Sideraemia (p ≤ 0.001); and serum cianocobalamine (p ≤ 0.001). We could not demonstrate statistically significant changes in the remaining parameters. However, under the presumption that the lack of evidence does not mean the evidence of the absence, that is to say, the results have been obtained from a small sample (N = 23) so that they may not be considered definitely conclusive. Considering the percentage of the loss of Body Mass Index excess as one of the quality indexes in bariatric surgery, we may state that Capella's gastric by-pass is efficient in obese patients with BMI ≤ 50 kg/m2, doubtfully effective in patients with BMI 50-60 kg/m2, and ineffective in super obese patients with BMI ≥ 60 kg/m2 (AU)

Determinación inmunohistoquímica y utilidad pronóstica del receptor del factor de crecimiento epidérmico en los tumores estromales gastrointestinales / No disponible

Introducción: el receptor del factor de crecimiento epidérmico,EGFR(HER-1), es un receptor de tirosina quinasas cuya activaciónpermite un aumento de la proliferación celular, angiogénesis,proceso metastásico y disminución de la apoptosis celular. Nuestroobjetivo es conocer el valor pronóstico de la inmunotinción deEGFR en tumores estromales gastrointestinales (GIST).Pacientes y método: estudio retrospectivo que incluye todoslos GIST intervenidos quirúrgicamente entre 1995-2007 en elServicio de Cirugía General y del Aparato Digestivo del HospitalGeneral de Ciudad Real. Variables clínicas: edad, sexo, clínica,mortalidad, recidiva. Variables patológicas: a) macroscópicas: localización,diámetro; b) microscópicas: necrosis tumoral, índicemitótico, tipo celular; y c) inmunohistoquímicas: vimentina (V9,Dako A/s); actina del músculo liso (HHF-35, Biogenex); CD34(QBEND/10); S100 (Policlonal Dako A/S); CD117 (c-kit Rabbit,antihuman polyclonal antibody, 1:600); PDGFR-alfa (Rabbitpolyclonal antibody, 1:50, Sta. Cruz Biotechnology). Variablesmoleculares pronósticas: P-53, PAb240 (DakoCytomation), 1:75,Ki-67, clona MIB1 (Dako), 1:120 y EGFR pharmDx™ Dako Autostainer(Dako, Dinamarca). Criterios de malignidad: criteriosde Fletcher.Resultados: entre 1995 y 2007, 35 GIST, fueron intervenidosquirúrgicamente en nuestro Servicio. Edad media: 61,11 ±11,02, siendo mujeres en el 62,9% de los casos. Debutaron conhemorragia digestiva en un 40%. La mediana de seguimiento fuede 28 meses (3-133). La mortalidad fue de 54,3%, con recidivadel 40%. Variables morfológicas: la localización más frecuente fuegástrica, 51,4% (18). Existió necrosis tumoral en un 57,1%, 20.El patrón celular fue fusocelular en un 57,1%, y epitelioide en un14,3%. El diámetro máximo fue de 9,58 ± 6,29. El índice mitóticopor 50 campos de gran aumento fue de 13,44 ± 16,08. En un51,45%, 18, fueron neoplasias de alto riesgo. Valores inmunohistoquímicos:CD117+, 85,7%. PDGFRA+, 85,7%. CD34+,77,1%. EGFR+, 62,9%. S100+, 34,3%. Actina+, 20%. Vimentina+,100%. p53+, 40%. ki67+, 10,71 ± 10,82. La expresión deEGFR no se relacionó con la recidiva y/o mortalidad del enfermo p = 0,156, y p = 0,332, respectivamente. El índice mitótico serelacionó con la mortalidad del enfermo, p = 0,02, y recidiva neoplásica,p = 0,013.Conclusión: en nuestra muestra no existió relación entre lainmunotinción de EGFR y el pronóstico del tumor estromal gastrointestinal

Introduction: the epidermal growth factor receptor, EGFR(HER-1), is a tyrosine kinase receptor. EGFR activation plays animportant role in increased cell proliferation, angiogenesis, anddecreased apoptosis. Our objective was to study EGFR immunoexpressionin GIST, as well as its prognostic value.Patients and method: a retrospective study that included allpatients operated on with a histologic diagnosis of GIST at Departmentof Surgery, Hospital General, Ciudad Real, between1995 and 2007. Clinical features: age, sex, manifestations, mortality,recurrence. Pathological features: origin, size, tumoralnecrosis, mitotic index, cell type. Immunohistochemical features:vimentin, (V9, Dako A/s); smooth muscle actin (HHF-35,Biogenex); CD34 (QBEND/10); S100 (Policlonal Dako A/S),CD117, (c-kit Rabbit, antihuman polyclonal antibody, 1:600);PDGFR-alfa (Rabbit polyclonal antibody, 1:50, Sta. Cruz Biotechnology).Prognostic molecular features: P-53, PAb240 (DakoCytomation)1:75; Ki-67, clona MIB1 (Dako), 1:120 y (EGFR)pharmDx™ Dako Autostainer (Dako, Denmark). Malignancycritera: Fletcher's critera.Results: from 1995 to 2007, 35 GISTs were resected in ourDepartment. Mean age: 61.11 ± 11.02, with a female predominanceof 62.9%. Initial clinical manifestation included digestivehemorrhage in 40%. Median follow-up was 28 months (3-133).Mortality was 54.3%, and recurrence rate was 40%. The mostfrequent origin was the stomach, 51.4%, (18). There was tumornecrosis in 57.1% (20). There were spindle-like cells in 57.1%,and epithelioid cells in 14.3%. Mean size was 9.58 ± 6.29. Mitoticindex per 50 high-power fields was 13.44 ± 16.08; 51.45%(18) were high-risk tumors. Immunohistochemical expression:CD117+, 85.7%. PDGFRA+, 85.7%. CD34+, 77.1%. EGFR+,62.9%. S100+, 34.3%. Actin+, 20%. Vimentin+, 100%. p53+,40%. ki67+, 10.71 ± 10.82. There was no correlation betweenEGFR expression and recurrence and/or mortality, p = 0.156and p = 0.332, respectively. Mitosis index related to mortality, p= 0.02, and recurrence, p = 0.013. Conclusion: in our study there was no relation betweenEGFR immunohistochemical expression and the prognosis of GIST (AU)

Hemorragia digestiva secundaria a lipoma duodenal / No disponible

No disponible

Íleo biliar subsecuente a una fístula colecistoduodenal (síndrome de Bouveret) / No disponible

No disponible

[Immunohistochemical expression of epidermal growth factor and its prognostic value for gastrointestinal stromal tumors]. / Determinación inmunohistoquímica y utilidad pronóstica del receptor del factor de crecimiento epidérmico en los tumores estromales gastrointestinales.

INTRODUCTION: The epidermal growth factor receptor, EGFR (HER-1), is a tyrosine kinase receptor. EGFR activation plays an important role in increased cell proliferation, angiogenesis, and decreased apoptosis. Our objective was to study EGFR immuno-expression in GIST, as well as its prognostic value. PATIENTS AND METHOD: A retrospective study that included all patients operated on with a histologic diagnosis of GIST at Department of Surgery, Hospital General, Ciudad Real, between 1995 and 2007. CLINICAL FEATURES: age, sex, manifestations, mortality, recurrence. Pathological features: origin, size, tumoral necrosis, mitotic index, cell type. Immunohistochemical features: vimentin, (V9, Dako A/s); smooth muscle actin (HHF-35, Biogenex); CD34 (QBEND/10); S100 (Policlonal Dako A/S), CD117, (c-kit Rabbit, antihuman polyclonal antibody, 1:600); PDGFR-alfa (Rabbit polyclonal antibody, 1:50, Sta. Cruz Biotechnology). Prognostic molecular features: P-53, PAb240 (DakoCytomation) 1:75; Ki-67, clona MIBI (Dako, Denmark). Malignancy criteria: Fletcher's criteria. RESULTS: From 1995 to 2007, 35 GISTs were resected in our Department. Mean age: 61.11 +/- 11.02, with a female predominance of 62.9%. Initial clinical manifestation included digestive hemorrhage in 40%. Median follow-up was 28 months (3-133). Mortality was 54.3%, and recurrence rate was 40%. The most frequent origin was the stomach, 51.4%, (18). There was tumor necrosis in 57.1% (20). There were spindle-like cells in 57.1%, and epithelioid cells in 14.3%. Mean size was 9.58 +/- 6.29. Mitotic index per 50 high-power fields was 13.44 +/- 16.08; 51.45% (18) were high-risk tumors. Immunohistochemical expression: CD117+, 85.7%. PDGFRA+, 85.7%. CD34+, 77.1%. EGFR+, 62.9%. S100+, 34.3%. Actin+, 20%. Vimentin+, 100%. p53+, 40%. ki67+, 10.71 +/- 10.82. There was no correlation between EGFR expression and recurrence and/ or mortality, p = 0.156 and p = 0.332, respectively. Mitosis index related to mortality, p = 0.02, and recurrence, p = 0.013. CONCLUSION: In our study there was no relation between EGFR immunohistochemical expression and the prognosis of GIST.

Enterocolitis neutropénica de mala evolución tras administración de docetaxel en enferma con cáncer de mama / Poor outcome neutropenic enterocolitis after treatment with docetaxel in a breast cancer patient

No disponible

Perfil molecular del cáncer colorrectal sin afectación ganglionar de mal pronóstico mediante la determinación inmunohistoquímica de p53, ki67, VEGF y metaloproteinasa 9. ¿Es útil como modelo pronóstico de recidiva? / Molecular pattern of poor prognostic colorectal cancer without nodular involvement by inmunohistochemical determination of p53, ki67, VEGF and metaloproteinase 9. It is useful as prognostic marker of recurrency?

No disponible

Masa multiquística benigna de cabeza de páncreas que simula la existencia de neoplasia quística pancreática / Benign multicystic mass in the head of pancreas simulating a pancreatic cystic neoplasia

No disponible

Aspectos inmunohistoquímicos y pronósticos del tumor adenocarcinoide de la ampolla de Vater / Tittle

No disponible

Cistoadenoma hepatobiliar con estroma mesenquimal, ¿una neoplasia con dependencia hormonal? / Hepatobiliary cystadenoma with mesenchymal stroma, a hormone dependent neoplasm?

No disponible